Cytovia Therapeutics Files New Patents for its Natural Killer Cell Engager Multifunctional Antibodies (FLEX-NK®) for the Treatment of Hematological and Solid Tumors
12 avr. 2021 11h11 HE
|
Cytovia Therapeutics
CAMBRIDGE, Mass. and AVENTURA, Fla., April 12, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Chimeric Antigen...
Cytovia Therapeutics’ Management to Present at Three Upcoming Conferences in March
08 mars 2021 10h24 HE
|
Cytovia Therapeutics
CAMBRIDGE, Mass., March 08, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Natural Killer (NK) and Chimeric...
Cytovia Therapeutics Partners with National Cancer Institute to Develop Novel Gene-Edited, iPSC-Derived GPC3 CAR NK Cells for the Treatment of Solid Tumors
13 janv. 2021 07h47 HE
|
Cytovia Therapeutics
CAMBRIDGE, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, an emerging biopharmaceutical company focusing on Natural Killer cells in cancer, announced today that it has signed a...
Cytovia Therapeutics announces plans to initiate in 2021 Clinical Development of Universal iPSC NK Cell Therapy for Hematological and Solid Tumors
08 déc. 2020 09h04 HE
|
Cytovia Therapeutics
CAMBRIDGE, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, an emerging NK cell therapeutics company, announced today that it plans to file with the FDA in 2021 an Investigational New...
Cytovia Therapeutics to Present at Jefferies Virtual London Healthcare Conference
12 nov. 2020 07h30 HE
|
Cytovia Therapeutics
NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, an emerging biopharmaceutical company developing Natural Killer Cell Therapeutics, today announced that it will participate in the...
Cytovia Therapeutics partners with Inserm to develop selective CD38 NK therapeutics and offer new treatment options for Multiple Myeloma patients
08 oct. 2020 06h00 HE
|
Cytovia Therapeutics
NEW YORK and PARIS, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics ("Cytovia"), an emerging biopharmaceutical company, announces today that it has entered a research and licensing agreement...
Cytovia Therapeutics to present at Jefferies Cell Therapy Virtual Summit, BIO Investor Forum and New York Stem Cell Foundation Conference in October 2020
29 sept. 2020 16h00 HE
|
Cytovia Therapeutics
NEW YORK, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, an emerging biopharmaceutical company developing Natural Killer Cell Therapeutics, today announced that it will participate in...
Cytovia Therapeutics and NYSCF Announce Filing of Provisional Patent for iPSC-Derived NK Cells to Produce Unlimited On-Demand NK and CAR-NK Cells for the Treatment of Cancer
25 août 2020 08h39 HE
|
Cytovia Therapeutics
NEW YORK, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, an emerging biopharmaceutical company and the New York Stem Cell Foundation (NYSCF) Research institute today announced the filing of...
Cytovia Therapeutics Licenses Productivity-Boosting Manufacturing Technology for Its NK Engager Multifunctional Antibodies From ProteoNic
12 août 2020 09h04 HE
|
Cytovia Therapeutics
NEW YORK and LEIDEN, the Netherlands, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc (Cytovia), an emerging biopharmaceutical company developing CAR NK cell therapy and NK engager...
Cytovia Therapeutics, Inc Adds Two Industry Leaders to Its Board of Directors
24 juin 2020 08h03 HE
|
Cytovia Therapeutics
NEW YORK, June 24, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc (“Cytovia”), an emerging biopharmaceutical company developing Natural Killer (NK) immunotherapies for cancer, today announces...